Contact a Rep
CONTACT A REP
Interested in connecting with an ANI Pharmaceuticals representative?

Fill out the request form below if you wish to be contacted with more information on Cortrophin Gel.

This form is for healthcare professionals only. If you are a patient looking to contact customer service, please call 1-800-434-1121 or email info@anipharmaceuticals.com.

* = Required

I confirm and agree to the following:*

I am a licensed US healthcare professional. I understand that this information may be used by ANI Pharmaceuticals and its affiliates and partners or third parties working on behalf of ANI Pharmaceuticals to contact me. I agree that the personal information I provide may be used by ANI Pharmaceuticals, or other companies acting on its behalf, to contact me via mail, email, or otherwise provide me with information about educational materials, market research, products, and services concerning Cortrophin Gel. I give my permission for ANI Pharmaceuticals to use my information for reasonable business purposes as permitted or required by law. Neither ANI Pharmaceuticals nor the companies working on its behalf may sell or rent my personal information except for as set forth in the ANI Pharmaceuticals Privacy Policy.

* = Required

Consider cortrophin gel as the next step for your appropriate patients

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:
  • Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.

Which of your patients with Severe Inflammatory Ophthalmic Diseases may be appropriate for Cortrophin Gel?

Purified Cortrophin Gel is indicated for severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:
  • Allergic conjunctivitis (conjunctiva)1,5,12#
  • Anterior segment inflammation (anterior segment)1-3
  • Chorioretinitis (choroid and retina)1,6
  • Choroiditis (choroid)1,5,6
  • Dry eye disease keraoconjunctivitis sicca15-17||
  • Iridocyclitis (ciliary body and iris)1,5-7
  • Iritis (iris)1,5-7‡
  • Keratitis (cornea)1,5,10,11¶
  • Keratoconjunctivitis8,9§
  • Optic neuritis (optic nerve)1,5
  • Panuveitis6†
  • Poster Cyclitis6
  • Retinal vasculitis (retina)5,6,13
  • Scleritis (sclera)6,11**
Other inflammatory processes involving the eye and its adnexa
  • Eyelid inflammation18
  • Lacrimal system disorders (eg, chronic dacryoadenitis)19,20
  • Orbital inflammation21
  • Orbital myositis22

*The anterior segment consists of the conjunctiva, cornea, anterior chamber, ciliary body, and iris.2
†Inflammation of all layers of the uvea (iris, ciliary body, and choroid).5,6

If you have patients with severe inflammatory ophthalmic diseases, Cortrophin Gel may be a potential next step in their treatment journey.

Learn more about potential appropriate patients

DOWNLOAD
Proposed Mechanism
of Action

Discover how ACTH may work by viewing its proposed mechanism of action (MOA).

Learn More
Prescribing
Cortrophin Gel

Access important
enrollment information.

Prescribe & Enroll
Provider & Patient
Resources

Explore downloadable resources, as well as educational materials for your appropriate patients, including injection guides.

Get Resources

‡Image courtesy of Maria Sieglinda von Nudeldorf, Creative Commons BY-SA 4.0, via Wikimedia Commons.  

§Image courtesy of Tony Ching, EyeWiki, American Academy of Ophthalmology. 

Originally published by and used with permission from Dove Medical Press Ltd. 

#Image courtesy of James Heilman, MD, Creative Commons BY 4.0, via Wikimedia Commons. 

||Image courtesy of the American Academy of Ophthalmology. 

**Image courtesy of Marc Yonkers, MD, Phd. Western Journal of Emergency Medicine.

References: 1. Purified Cortrophin Gel. Package insert. ANI Pharmaceuticals, Inc. 2. Akhter MH, et al. Gels. 2022;8(2):82. 3. Maring M, et al. Ocul Immunol Inflamm. 2022;30(2):357-363. 4. Harthan JS, et al. Clin Optom 2016;8:23-35. 5. Bielory L. J Allergy Clin Immunol. 2000;106(5):805-816. 6. Jabs DA, et al. Am J Ophthalmol. 2005;140(3):509-516. 7. Wikimedia Commons. Accessed January 9, 2026. https://commons.wikimedia.org/wiki/File:Vascularised_posterior_synechia.jpg 8. Sacchetti M, et al. Life. 2021;11(10):1012. 9. Ching T. Vernal Keratoconjunctivitis. American Academy of Ophthalmology. EyeWiki. Accessed January 9, 2026. https://eyewiki.org/File:AA0_4068.jpg 10. Koganti R, et al. Exp Eye Res. 2021;205:108483. 11. Sabhapandit S, et al. Clin Optom. 2022;16:3547-3557. 12. Wikimedia Commons. Accessed January 9, 2026. https://commons.wikimedia.org/wiki/File:Allergicconjunctivitis.jpg 13. Walton RC, Ashmore ED. Curr Opin Ophthalmol. 2003;14(6):413-419. 14. Gilani CJ, et al. West J Emerg Med. 2017;18(3):509-517. 15. Shen Lee B, et al. Ophthalmol Ther. 2022;11(4):1333-1369. 16. Rolando M, Barabino S. Int J Mol Sci. 2023;24(2):1458. 17. Milner MS, et al. Curr Opin Ophthalmol. 2017;28:3-47. 18. Bernardes TF, Bonfioli AA. Semin Ophthalmol. 2010;25(3):79-83. 19. Zoukhri D. Exp Eye Res. 2006;82(5):885-898. 20. Sundar G, et al. American Academy of Ophthalmology. EyeWiki. Accessed January 9, 2026. https://eyewiki.aao.org/Dacryoadenitis 21. Lutt JR, et al. Semin Arthritis Rheum. 2008;37(4):207-222. 22. Brent H, Sidlow R. Clin Pediatr. 2017;56(4):385-388.

Indications
Important Safety Information
Expand ISI
IndicationsExpand ISI

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

  • Acute exacerbations of multiple sclerosis.
  • Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
  • Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
  • Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
  • Atopic dermatitis and serum sickness.
  • Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
  • Symptomatic sarcoidosis.
  • Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
Important Safety InformationExpand ISI
Contraindications
  • Cortrophin Gel is contraindicated for intravenous administration.
  • Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.
Warnings and Precautions
  • Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
  • Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
  • Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
  • Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
  • Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
  • Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
  • Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
  • Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
  • Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
  • Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
  • Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
  • Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
  • Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
  • Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
  • Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.

Indications

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

  • Acute exacerbations of multiple sclerosis.
  • Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
  • Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
  • Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
  • Atopic dermatitis and serum sickness.
  • Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
  • Symptomatic sarcoidosis.
  • Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
Important Safety InformationContraindications
  • Cortrophin Gel is contraindicated for intravenous administration.
  • Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.
Warnings and Precautions
  • Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
  • Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
  • Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
  • Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
  • Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
  • Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
  • Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
  • Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
  • Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
  • Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
  • Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
  • Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
  • Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
  • Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
  • Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.